

研究成果の刊行に関する一覧表

書籍

著者氏名	論文タイトル名	書籍全体の 編集者名	書籍名	出版社名	出版地	出版年	ページ
橋本亮太	第IX章 精神疾患 「統合失調症」	門脇 孝, 小室 一成, 宮地 良樹	日常診療に活かす診療ガイドライン UP-TO-DATE	メディカルレビュー一社	東京	2022	596-600
木田直也、橋本亮太	クロザビン療法	一般社団法人 内科系学会社会保険連合	標準的医療説明－インフォームド・コンセントの最前	医学書院	東京	2021	243-4

論文

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
<u>Yasui-Furukori N,</u> Muraoka H, Hasegawa N, Ochi S, Numata S, Hori H, Hishimoto A, Onitsuka T, Ohi K, Hashimoto N, Nagasawa T, Takaesu Y, Inagaki T, Tagata H, Tsuboi T, Kubota C, Furihata R, Iga JI, Iida H, Miura K, Matsumoto J, Yamada H, Watanabe K, <u>Inada K</u> , Shimoda K, <u>Hashimoto R.</u>	Association between the examination rate of treatment-resistant schizophrenia and the clozapine prescription rate in a nationwide dissemination and implementation study.	Neuropsychopharmacol Rep.	42(1)	3-9	2022

Kikuchi M, Nakazawa T, Kinoshita M, Yamamori H, Yasuda Y, Fujimoto M, <u>Hashimoto R</u> , Numata S.	Methylation Analysis in Monozygotic Twins with Treatment- Resistant Schizophrenia and Discordant Responses to Clozapine.	Front Psychiatry, section Schizophrenia	12	734606	2021
Imazu S, Hata T, Toyoda K, Kubo Y, Yamauchi S, Kinoshita S, Nishihara M, <u>Inada K</u> , <u>Kanazawa T</u>	Safety profile of clozapine: Analysis using national registry data in Japan.	J Psychiatr Res	141	116-23	2021
Ninomiya K, Saito T, Okochi T, Taniguchi S, Shimasaki A, Aoki R, Hata T, Mushiroda T, <u>Kanazawa T</u> , Ikeda M, Iwata N.	Cost effectiveness of pharmacogenetic- guided clozapine administration based on risk of HLA variants in Japan and the UK.	Transl Psychiatry.	11(1)	362	2021
Japanese Society of Neuropsychophar- macology.	Japanese Society of Neuropsychopharm- acology: "Guideline for Pharmacological Therapy of Schizophrenia".	Neuropsych opharmacol Rep.	41(3)	266-324	2021

Tsukiji M, Sasaki T, Nakata Y, Ota K, Aoki T, Hara K, Mamada T, Nakane J, Kogure M, Seki R, Idemoto K, Hashimoto T, Koishikawa H, Moriyama T, Suzuki T, Kanahara N, Ishii I, Iyo M, Niitsu T.	Risk factors for early-phase clozapine discontinuation: A nested case-control study.	Asian J Psychiatr.	62	102745	2021
Toyoda K, Hata T, Yamauchi S, Kinoshita S, Nishihara M, Uchiyama K, Inada K, Kanazawa T.	Clozapine Is Better Tolerated in Younger Patients: Risk Factors for Discontinuation from a Nationwide Database in Japan.	Psychiatry Investigatio n	18(2)	101-9	2021

Ichihashi K, Kyou Y, Hasegawa N, <u>Yasui-Furukori</u> <u>N</u> , Shimnizu Y, Hori H, Hashimoto N, Ide K, Imamura Y, Yamada H, Ochi S, Iga J, Takaesu Y, Ohi K, Tsuboi T, Iida H, Yamagata H, Hishimoto A, Horai T, Usami M, Makinodan M, Nagasawa T, Komatsu H, Kido M, Muraoka H, Atake K, Takeshima M, Kubota C, Inagaki T, Tamai S, Kishimoto T, Furihata R, Matsumoto J, Miura K, <u>Inada</u> <u>K</u> , Watanabe K, Kasai K, <u>Hashimoto R</u> .	The characteristics of patients receiving psychotropic pro re nata medication at discharge for the treatment of schizophrenia and major depressive disorder: A nationwide survey from the EGUIDE project.	Asian J Psychiatr,	69	103007	2022
---	--	-----------------------	----	--------	------

Onitsuka T, Hirano Y, Nemoto K, Hashimoto N, Kushima I, Koshiyama D, Koeda M, Takahashi T, Noda Y, Matsumoto J, Miura K, Nakazawa T, Hikida T, Kasai K, Ozaki N, <u>Hashimoto R.</u>	Trends in big data analyses by multicenter collaborative translational research in psychiatry.	Psychiatry Clin Neurosci	76(1)	1-14	2022
Hashimoto N, <u>Yasui-Furukori</u> , N, Hasegawa N, Ishikawa S, Numata S, Hori H, Iida H, Ichihashi K, Furihata R, Murata A, Tsuboi T,	Characteristics of discharge prescriptions for patients with schizophrenia or major depressive disorder: Real-world evidence from the Effectiveness of Guidelines for	Asian J Psychiatr,	63	102744	2021

Takeshima M, Kyou Y, Komatsu H, Kubota C, Ochi S, Takaesu Y, Usami M, Nagasaki T, Hishimoto A, Miura K, Matsumoto J, Ohi K, Yamada H, <u>Inada K</u> , Watanabe K, Shimoda K, <u>Hashimoto R</u> .	Dissemination and Education (EGUIDE) psychiatric treatment project.				
Numata S, Nakataki M, Hasegawa N, Takaesu Y, Takeshima M, Onitsuka T, Nakamura T, Edagawa R, Edo H, Miura K, Matsumoto J, Yasui- <u>Furukori</u> <u>N</u> , Kishimoto T, Hori H, Tsuboi T, Yasuda Y, Furihata R, Muraoka H, Ochi S, Nagasaki T, Kyou Y, Murata A, Katsumoto E,	Improvements in the degree of understanding the treatment guidelines for schizophrenia and major depressive disorder in a nationwide dissemination and implementation study.	Neuropsych opharmacol Rep,	41(2)	199-206	2021

Ohi K, Hishimoto A, <u>Inada K</u> , Watanabe K, <u>Hashimoto R</u> .					
Ito S, Matsumoto J, Sakai Y, Miura K, Hasegawa N, Yamamori H, Ishimaru K, Kim Y, <u>Hashimoto R</u> .	Positive association between insight and attitudes toward medication in Japanese patients with schizophrenia: Evaluation with the Schedule for Assessment of Insight (SAI) and the Drug Attitude Inventory - 10 Questionnaire (DAI- 10).	Psychiatry Clin Neurosci,	75(5)	187-8	2021
Toyoda K, Hata T, Yamauchi S, Kinoshita S, Nishihara M, Uchiyama K, <u>Inada K</u> , <u>Kanazawa T</u>	A descriptive study of 10-year clozapine use from the nationwide database in Japan.	Psychiatry Research	297	1-6	2021